摘要
目的探讨苦参碱联合胸腺五肽对经腹腔热化疗干预的卵巢癌大鼠一般状态的影响。方法将58只大鼠随机分为对照组和观察组,最后每组各有23只造模成功。2组造模成功大鼠均进行腹腔热化疗(顺铂)并同时给予胸腺五肽腹腔灌注,观察组在此基础上给予苦参碱腹腔灌注,共干预3周。比较2组大鼠造模前后及干预后大鼠体质量、腹围,取血检测CK、AST、LDH水平和CA125水平。采血完成后处死大鼠,观察腹腔内情况,测定腹水量及肿瘤质量。结果 2组大鼠造模后体质量、腹围及血清酶学指标、CA125水平均明显高于造模前(P均<0.05),但是2组间比较差异均无统计学意义(P均>0.05);2组大鼠干预后体质量、腹围及血清酶学指标、CA125水平均明显高于造模后(P均<0.05),但观察组均明显低于对照组(P均<0.05)。干预后观察组腹水量及肿瘤质量均明显低于对照组(P均<0.05)。结论行腹腔热化疗的卵巢癌大鼠给予苦参碱联合胸腺五肽,有助于改善卵巢癌大鼠的一般状态并抑制肿瘤生长,为临床实践提供一定理论基础。
Objective It is to study the effects of matrine combined with thymopeptide- 5 on immune function in rats with ovariancarcinoma treated by intraperitoneal hyperthermic chemotherapy. Methods 46 rats which were successfully modelled ovariancarcinoma were randomly divided into two groups： observation group（ n = 23） and control group（ n = 23）. The rats in both groups were given intraperitoneal hyperthermic chemotherapy（ cis-platinum） and thymopeptide- 5,whereas the rats in the observation group were given matrine on this basic,the course of treatment were 3 weeks. The waist circumference,weight,ascitic fluid,the weight of tumor mass,liver enzyme and the level of CA125 in the two groups of rats were compared before and after molding and after treatment. Results The level of waist circumference,weight,CA125 and liver enzyme indexes were higher than that before treatment in both groups（ P 0. 05）,but the indexes in the observation group were lower than that in control group（ P 0. 05）. Ascitic fluid,the weight of tumor mass were smaller in the observation group than that in control group after treatment（ P 0. 05）. Conclusion Matrine combined with thymopeptide- 5 can improve the general state and inhibit the growth of tumor in rats with ovariancarcinoma treated by intraperitoneal hyperthermic chemotherapy,and provide certain theoretical basis for clinical practice.
出处
《现代中西医结合杂志》
CAS
2016年第29期3196-3198,共3页
Modern Journal of Integrated Traditional Chinese and Western Medicine
基金
辽宁省自然科学基金项目(2013225021)
关键词
卵巢癌
苦参碱
胸腺五肽
腹腔热化疗
CA125
ovariancarcinoma
matrine
thymopeptide-5
intraperitoneal hyperthermic chemotherapy
general state
CA125
